key: cord-0831045-ay6sol9k
authors: Stokes, W.; Berenger, B.; Singh, T.; Adeghe, I.; Schneider, A.; Portnoy, D.; King, T.; Scott, B.; Pabbaraju, K.; Shokoples, S.; Wong, A. A.-T.; Gill, K.; Turnbull, L.; Hu, J.; Tipples, G.
title: Acceptable Performance of the Abbott ID NOW Among Symptomatic Individuals with Confirmed COVID-19
date: 2020-12-30
journal: nan
DOI: 10.1101/2020.12.24.20248786
sha: 74f2d9131bf04803ea8c16b1c43f77435172c258
doc_id: 831045
cord_uid: ay6sol9k

INTRODUCTION Point of care diagnostic tests for SARS-CoV-2, such as the ID NOW, have great potential to help combat the COVID-19 pandemic. The ID NOW is approved by the United States Food and Drug Administration (FDA) for the detection of SARS-CoV-2 in symptomatic individuals within the first 7 days of symptom onset for COVID-19 if tested within 1 hour of specimen collection. However, clinical data on the performance of the ID NOW is limited, with many studies deviating from the manufacturer instructions and/or having small sample size. METHODS Adults with COVID-19 in the community or hospital were recruited into the study. Paired throat swabs were collected, with one throat swab transported immediately in an empty sterile tube to the laboratory for ID NOW testing, and the other transported in universal transport media and tested by an in-house SARS-CoV-2 RT-PCR assay targeting the E-gene. Positive percent agreement (PPA) was calculated. RESULTS 133 individuals were included in the study. 129 samples were positive on either the ID NOW and/or RT-PCR. Assuming any positive result on either assay represents a true positive, PPA of the ID NOW compared to RT-PCR with 95% confidence intervals was 89.1% [82.0% - 94.1%] and 91.6% [85.1% - 95.9%], respectively. When analyzing individuals with symptoms within 7 days and who had the ID NOW performed within an hour, ID NOW PPA increased to 98.2%. DISCUSSION In this study, SARS-CoV-2 results from the ID NOW were reliable, especially when testing was adhered to manufacturer recommendations.

Abbott ID NOW has been shown to have excellent specificity (~100%) but sensitivity varies 85 widely between studies (48.0% -94.1%). [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] In addition, many of these studies suffer from poor 86 study design such as comparing nasopharyngeal to nasal specimens, deviating from the product 87 insert or having major delays in testing specimens on the ID NOW. Only two studies adhered to 88 how to perform throat swabs using the ClassiqSwabs (COPAN Diagnostics, California, United 115 States) and the throat swab provided in the ID NOW testing kits (Abbott, Illinois, United 116 States). 18 Throat swabs were collected from both sides of the oropharynx and the posterior 117 pharyngeal wall under the uvula. Throat swabs were collected approximately one minute apart 118 and the order in which throat swabs were collected was recorded. 119 120 For each paired throat swab, one was placed into a dry 15mL conical centrifuge tube (Fisher 121 SARS-CoV-2 on the Cobas 6800 instrument was performed according to manufacturer's 137 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Two throat swabs were collected from asymptomatic individuals at low risk of having COVID-150 19 (no recent travel, no exposures). One throat swab was tested immediately (<2 minutes) on the 151 ID NOW instrument. The other throat swab was tested by RT-PCR as explained above. To 152 assess for cross-reactivity, retrospective samples containing high concentrations of various 153 respiratory viruses, stored in UTM, were tested by aliquoting 400uL of sample into the ID NOW 154 blue specimen receiver. These samples were previously tested by the NxTAG® Respiratory 155

Pathogen Panel (Luminex, Tx, United States) or the CDC influenza SARS-CoV-2 multiplex 156 assay . The ability of the ID NOW to process this volume of UTM was confirmed by testing four 157 retrospective positive SARS-CoV-2 samples, in UTM, and showing that they could be detected 158 (data not shown, Ct values ranging from 21 -28). 159 160 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 30, 2020. ; https://doi.org/10.1101/2020.12.24.20248786 doi: medRxiv preprint

One hundred and fifty-two patients were recruited for this study. Fourteen individuals were 162 asymptomatic at the time of COVID-19 diagnosis and at time of study collection and were 163 therefore excluded from analysis (sub-analysis provided in the supplementary material). The date 164 of symptom onset for two individuals was not captured at time of consent and they could not be 165 reached later for clarification, and therefore excluded. Three samples were excluded as samples 166

were lost for RT-PCR testing (all were ID NOW positive). Symptom details were not recorded 167 for two individuals but they were still included in the analysis as symptom onset was known and 168 they were still symptomatic at the time of collection. This resulted in the inclusion of 133 169 individuals in our analysis and their characteristics are provided in Table 1 . (19.1%), shortness of breath (13.0%), rhinorrhea (11.5%), nausea/vomiting (3.8%) and other 176 including chest pain, diarrhea, loss of appetite or arthralgias (7.6%). 177 178 Mean duration of symptoms at the time of collection was 6.9 (median=7, range=1 -17) days. 179

Seventy-five percent (n=100) of individuals were within the 7-day symptom onset window, 180 62.4% (n=83) of individuals had their samples tested on the ID NOW within 1 hour from 181 collection, and 46.6% (N=62) met the regulatory agency approved criteria for testing on the ID 182 NOW (symptom onset ≤ 7 days and ID NOW test conducted within an hour from collection). 183 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (Table 5) . RT-PCR samples were more 198 likely to be positive if the sample was tested on individuals with symptoms ≤ 7 days (Table S2 ). 199 200 When tested in triplicate using RT-PCR followed by triplicate testing by the CDC method and 201 testing on the Cobas 6800, 5/10 (50.0%) RT-PCR negative samples, with paired positive ID 202 NOW swabs, resolved as positive. One sample was unable to undergo additional testing. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 30, 2020. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Limitations of our study include the low number of hospitalized patients recruited such that we 248 cannot make strong conclusions about the ID NOW performance among this population. The 249 majority of throat swabs tested on the ID NOW were collected before the comparator swab 250 (78.0%). However, we did not observe any difference in ID NOW or RT-PCR positivity rate 251 when comparing patients who had ID NOW throat swab collected first vs second (Table 5 and 252 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 30, 2020. In conclusion, the ID NOW was found to be a comparable method to our RT-PCR for the 273 detection of SARS-CoV-2 among individuals with symptomatic COVID-19 infection. PPA was 274 enhanced when tested on individuals with symptom onset ≤ 7 days and when time from 275 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 30, 2020. ; https://doi.org/10.1101/2020.12.24.20248786 doi: medRxiv preprint collection to testing was within one hour. These results reassure us that the ID NOW is a reliable 276 test method in symptomatic individuals, especially when adhering to the FDA-approved 277 indications and recommendations for testing. Given the speed and low-complexity of ID NOW 278 testing, these instruments can truly be used as a point of care device. As such, they will play an 279 impactful role in combating the COVID-19 pandemic by improving testing in settings where 280 low-volume rapid (<1h) turnaround times are much needed, such as among difficult to reach 281 populations (e.g. homeless), inpatients with suspected nosocomial infection, and in rural areas 282

where access to a laboratory is limited because transportation delays are significant. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 30, 2020. ; https://doi.org/10.1101/2020.12.24.20248786 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 30, 2020. ; https://doi.org/10.1101/2020.12.24.20248786 doi: medRxiv preprint preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 30, 2020. ; https://doi.org/10.1101/2020.12.24.20248786 doi: medRxiv preprint

United States Food and Drug Administration. ID NOW COVID-19 -instructions for use

A comparison of five SARS-CoV-2 molecular 345 assays with clinical correlations

Comparison of Abbott ID NOW COVID-19 rapid 347 molecular assay to cepheid Xpert Xpress SARS-CoV-2 assay in dry nasal swabs

Commercial severe acute respiratory syndrome 350 coronavirus 2 (SARS-CoV-2) molecular assays: Superior analytical sensitivity of cobas 351 SARS-CoV-2 relative to NxTAG CoV extended panel and ID NOW COVID-19 352 test

AHS collection guide. Alberta Health Services. Collection of Nasopharyngeal and Throat 358 Swab for Detection of Respiratory Infection

Sensitivity of nasopharyngeal, 362 nasal and throat swab for the detection of SARS-CoV-2. 2020